+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hyperlipidemia Drugs Market by Drug Class, Distribution Channel, End User, Route of Administration, Patient Type, Hyperlipidemia Type - Global Forecast to 2030- Product Image
Hyperlipidemia Drugs Market by Drug Class, Distribution Channel, End User, Route of Administration, Patient Type, Hyperlipidemia Type - Global Forecast to 2030- Product Image
Sale

Hyperlipidemia Drugs Market by Drug Class, Distribution Channel, End User, Route of Administration, Patient Type, Hyperlipidemia Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888967
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The hyperlipidemia drugs market is evolving rapidly with innovations in therapeutic modalities and regulatory shifts driving new opportunities. Senior decision-makers require a clear, actionable overview of the dynamic landscape to navigate strategic investments and anticipate emerging risks in hyperlipidemia drug development and commercialization.

Market Snapshot: Hyperlipidemia Drugs Market Growth

The Hyperlipidemia Drugs Market grew from USD 24.31 billion in 2024 to USD 25.30 billion in 2025. It is expected to continue expanding at a CAGR of 4.05%, reaching USD 30.85 billion by 2030. This growth is being shaped by advances in molecular biology, evolving regulatory policies, and increasing demand for personalized treatment approaches that address both primary and secondary lipid disorders. As targeted therapeutics gain traction, decision-makers must stay ahead of trends in pricing, access, and regional expansion to ensure robust market positioning.

Scope & Segmentation

This comprehensive report offers detailed segmentation that empowers stakeholders to identify and address strategic opportunities across the hyperlipidemia therapeutic landscape.

  • Drug Classes: Statins; Bile Acid Sequestrants (Cholestyramine, Colesevelam); Fibrates (Fenofibrate, Gemfibrozil); Omega-3 Fatty Acids (DHA, EPA); PCSK9 Inhibitors (Monoclonal Antibodies, siRNA).
  • Distribution Channels: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies.
  • End Users: Clinics; Home Care; Hospitals; Specialty Centers.
  • Routes of Administration: Injectable; Oral.
  • Patient Types: Adult; Pediatric.
  • Hyperlipidemia Types: Primary; Secondary.
  • Geographic Coverage: Americas (including detailed U.S. regional data, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (notable countries such as UK, Germany, France, and others); Asia-Pacific (including China, India, Japan, Australia, among others).
  • Leading Companies Profiled: Amgen Inc., Sanofi S.A., Regeneron Pharmaceuticals, Inc., Novartis AG, AstraZeneca PLC, Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Esperion Therapeutics, Inc., Ionis Pharmaceuticals, Inc.

Key Takeaways for Senior Decision-Makers

  • Therapeutic innovation is re-shaping hyperlipidemia management, with the introduction of RNA-based therapies and monoclonal antibodies diversifying options beyond established statins.
  • Digital health solutions, such as AI-driven risk assessment tools and remote lipid monitoring, are boosting adherence and enabling more effective clinical decision-making.
  • Market access is increasingly determined by value-based reimbursement frameworks that prioritize outcomes and real-world evidence for formulary success.
  • Segmentation points to growth avenues in both specialized injectable therapies and convenient oral agents, allowing differentiation by patient profile and healthcare setting.
  • Cross-sector partnerships—especially between incumbent pharmaceutical firms and biotech innovators—are accelerating drug development cycles and optimizing commercialization pathways.
  • Regional differences in policy, patient access, and technology adoption highlight the need for tailored strategies across mature and emerging markets.

Tariff Impact: U.S. Supply Chain and Cost Shifts

The introduction of U.S. tariffs on select pharmaceutical ingredients in 2025 has increased production costs and compelled manufacturers to reconsider sourcing and nearshoring strategies. Partnerships with domestic chemical manufacturers have become pivotal for resilient supply chains. Innovation in manufacturing efficiency and supplier diversification have partially offset cost pressures, while payers and providers intensify negotiations to manage budgetary impact. These dynamics stress the ongoing importance of agile procurement and transparent cost controls as competitive advantages.

Methodology & Data Sources

Insights are synthesized using primary research via expert interviews with clinicians, regulatory specialists, payers, and patient advocates, combined with secondary research from clinical, regulatory, and financial sources. Data triangulation and scenario modeling underpin analysis, ensuring findings reflect real-world market realities and stakeholder needs. Rigorous review safeguards accuracy and objectivity across every research phase.

Why This Report Matters

  • This report delivers actionable intelligence that supports senior executives in refining market entry and expansion strategies by highlighting growth segments and evolving patient needs.
  • It equips market access, R&D, and commercial teams with the granular data and regional insights needed to de-risk investments and accelerate decision-making in a complex regulatory climate.

Conclusion

The hyperlipidemia drugs market is defined by rapid innovation, heightened regulatory complexity, and shifting cost drivers. Organizations leveraging the latest insights, diverse drug portfolios, and collaborative strategies will be well-positioned to capture sustained growth and improve patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hyperlipidemia Drugs Market, by Drug Class
8.1. Introduction
8.2. Bile Acid Sequestrants
8.2.1. Cholestyramine
8.2.2. Colesevelam
8.3. Fibrates
8.3.1. Fenofibrate
8.3.2. Gemfibrozil
8.4. Omega-3 Fatty Acids
8.4.1. DHA
8.4.2. EPA
8.5. PCSK9 Inhibitors
8.5.1. Monoclonal Antibodies
8.5.2. SiRNA
8.6. Statins
9. Hyperlipidemia Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Hyperlipidemia Drugs Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Home Care
10.4. Hospitals
10.5. Specialty Centers
11. Hyperlipidemia Drugs Market, by Route of Administration
11.1. Introduction
11.2. Injectable
11.3. Oral
12. Hyperlipidemia Drugs Market, by Patient Type
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Hyperlipidemia Drugs Market, by Hyperlipidemia Type
13.1. Introduction
13.2. Primary
13.3. Secondary
14. Americas Hyperlipidemia Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Hyperlipidemia Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Hyperlipidemia Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Amgen Inc.
17.3.2. Sanofi S.A.
17.3.3. Regeneron Pharmaceuticals, Inc.
17.3.4. Novartis AG
17.3.5. AstraZeneca PLC
17.3.6. Pfizer Inc.
17.3.7. Eli Lilly and Company
17.3.8. Merck & Co., Inc.
17.3.9. Esperion Therapeutics, Inc.
17.3.10. Ionis Pharmaceuticals, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. HYPERLIPIDEMIA DRUGS MARKET MULTI-CURRENCY
FIGURE 2. HYPERLIPIDEMIA DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. HYPERLIPIDEMIA DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. HYPERLIPIDEMIA DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. HYPERLIPIDEMIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HYPERLIPIDEMIA DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DHA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY EPA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SIRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PRIMARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SECONDARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 66. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 67. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 68. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 77. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 83. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 125. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 127. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 128. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 129. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 135. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 137. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 138. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 139. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 144. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 155. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 157. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 158. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 159. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 165. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 166. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 167. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 168. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 169. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 174. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 175. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 185. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 195. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 205. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 206. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 207. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 208. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 209. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 214. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 215. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 216. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 225. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 227. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 228. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 229. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 230. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 235. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 237. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 238. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 239. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 244. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 245. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 255. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 256. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 257. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 265. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 266. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 267. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 268. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 269. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 270. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 275. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 276. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 277. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 278. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 279. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 280. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 284. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 285. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 286. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 287. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 295. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 296. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 297. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 298. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 299. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 300. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 303. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 304. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 305. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 306. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 307. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 308. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 309. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 310. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 312. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 313. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 314. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 315. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 316. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 317. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 318. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 319. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 320. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HYPERLIPIDEMIA TYPE, 2018-2030 (USD MILLION)
TABLE 325. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 326. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 327. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 328. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 329. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 330. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD M

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Hyperlipidemia Drugs market report include:
  • Amgen Inc.
  • Sanofi S.A.
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Pfizer Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Esperion Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 25.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 30.85 Billion
Compound Annual Growth Rate4.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Hyperlipidemia Drugs - Global Strategic Business Report - Product Image

Hyperlipidemia Drugs - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Hyperlipidemia Drugs Market Report by Drug Type, End User, and Region 2024-2032 - Product Image

Hyperlipidemia Drugs Market Report by Drug Type, End User, and Region 2024-2032

  • Report
  • 146 Pages
  • Global
From
Hyperlipidemia Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Hyperlipidemia Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 86 Pages
  • Global
From
Antihyperlipidemic Drugs Market Size, Share, Trends and Forecast by Drug Class, Route of Administration, Distribution Channel, and Region, 2025-2033 - Product Image

Antihyperlipidemic Drugs Market Size, Share, Trends and Forecast by Drug Class, Route of Administration, Distribution Channel, and Region, 2025-2033

  • Report
  • 149 Pages
  • Global
From
Hyperlipidemia - Pipeline Insight, 2025 - Product Image

Hyperlipidemia - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the Hyperlipidemia Drug Market

The Hyperlipidemia Drug market is a subset of the Cardiovascular Drugs market, which focuses on the treatment of high levels of lipids in the blood. Hyperlipidemia is a condition that can lead to an increased risk of heart disease, stroke, and other cardiovascular diseases. Common treatments for hyperlipidemia include statins, fibrates, and cholesterol absorption inhibitors. Statins are the most commonly prescribed drugs for hyperlipidemia, as they are effective in reducing cholesterol levels. Fibrates are used to reduce triglyceride levels, while cholesterol absorption inhibitors reduce the absorption of cholesterol from the diet. Some companies in the Hyperlipidemia Drug market include Pfizer, Merck, AstraZeneca, Sanofi, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.